Arbutus Biopharma
(NASDAQ) ABUS
Arbutus Biopharma Financials at a Glance
Market Cap
$879.04M
Revenue (TTM)
$191.45M
Net Income (TTM)
$160.72M
EPS (TTM)
$0.82
P/E Ratio
5.41
Dividend
$0.00
Beta (Volatility)
0.97 (Low)
Dividend
$0.00
Beta (Volatility)
0.97 (Low)
Price
$4.47
Volume
117,106
Open
$4.50
Price
$4.47
Volume
117,106
Open
$4.50
Previous Close
$4.47
Daily Range
$4.40 - $4.57
52-Week Range
$3.04 - $5.10
Estimated Earnings Date
Apr 30, 2026
Dividend
$0.00
Beta (Volatility)
0.97 (Low)
Price
$4.47
Volume
117,106
Open
$4.50
Previous Close
$4.47
Daily Range
$4.40 - $4.57
52-Week Range
$3.04 - $5.10
Estimated Earnings Date
Apr 30, 2026
ABUS News
ABUS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Arbutus Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
19
CEO
Lindsay Androski, CFA, MBA
Website
www.arbutusbio.comHeadquarters
Warminster, PA 18974, US
ABUS Financials
Key Financial Metrics (TTM)
Gross Margin
99.98%
Operating Margin
80.79%
Net Income Margin
83.95%
Return on Equity
129.32%
Return on Capital
-33.49%
Return on Assets
57.99%
Earnings Yield
18.48%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$879.04M
Shares Outstanding
197.54M
Volume
117.11K
Avg. Volume
1.78M
Financials (TTM)
Gross Profit
$191.41M
Operating Income
$154.67M
EBITDA
$160.85M
Operating Cash Flow
-$34.36M
Capital Expenditure
$8.11M
Free Cash Flow
-$34.36M
Cash & ST Invst.
$95.23M
Total Debt
$631.00K
Arbutus Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$179.13M
+10054.5%
Gross Profit
$179.12M
+2589.4%
Gross Margin
99.99%
N/A
Market Cap
$879.04M
N/A
Market Cap/Employee
$46.27M
N/A
Employees
19
N/A
Net Income
$169.70M
+791.9%
EBITDA
$169.72M
+802.4%
Quarterly Fundamentals
Total Cash
$95.23M
-15.5%
Total Debt
$631.00K
-88.7%
Accounts Receivable
$1.31M
+11.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$631.00K
+12.1%
Return on Assets
57.99%
N/A
Return on Invested Capital
56.85%
N/A
Free Cash Flow
-$8.11M
+39.4%
Operating Cash Flow
-$8.11M
+39.4%